MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines

D H Teng1, R Hu, H Lin

  • 1Myriad Genetics Inc., Salt Lake City, Utah 84108, USA. tengd@myriad.com

Cancer Research
|December 11, 1997
PubMed

Insights

The MMAC1/PTEN gene, a tumor suppressor, shows alterations in various human cancers. Further investigation revealed inactivating mutations and deletions in diverse tumor types, supporting its role in cancer development.

Area of Science:

  • Oncology
  • Human Genetics
  • Molecular Biology

Background:

  • The MMAC1/PTEN gene, located at chromosome band 10q23, is a candidate tumor suppressor.
  • Sequence alterations in MMAC1/PTEN have been observed in glioma, breast, prostate, and kidney tumors.

Purpose of the Study:

  • To investigate the mutational profile of the MMAC1/PTEN gene in a wide range of human cancers.
  • To identify allelic losses and sequence alterations at the 10q23 locus in tumor specimens and cell lines.

Main Methods:

  • Screening of human tumor specimens and cancer cell lines for 10q23 allelic losses.
  • Analysis of MMAC1/PTEN sequence alterations, including missense, splicing, and nonsense mutations.
  • Detection of homozygous deletions in tumor cell lines.

Main Results:

  • Loss of heterozygosity (LOH) at the MMAC1 locus was found in approximately 50% of examined samples.
  • MMAC1 variants were detected in 10% of primary tumors with LOH, with higher frequency in glioblastoma (23%).
  • Microsequence alterations (16%) and homozygous deletions (14%) of MMAC1 were identified in tumor cell lines.

Conclusions:

  • Inactivating MMAC1/PTEN alterations occur in multiple human cancer types.
  • The study identified novel MMAC1 alterations in melanoma and pediatric glioblastomas.
  • A putative pseudogene of MMAC1 was discovered on chromosome 9.

Related Concept Videos